Biovail acquired the marketing and distribution rights to Vasotec (enalapril) and Vaseretic (enalapril with hydrochlorothiazide) from Merck & Co. for approximately US$95 M. The agreement calls for Merck to manufacture and supply the products to Biovail temporarily during transition period.